Medicare Coverage of Cxbladder Expected to Cease
11th September 2023
Pacific Edge today announces Medicare coverage of Cxbladder tests in the US market is expected to cease from 17 July 2023. Read More
US Urological Societies Call for Medicare LCD Revision
29th August 2023
Pacific Edge welcomes the strong industry and clinician support it has received during the open public meetings to take feedback on draft local coverage determinations (LCDs) that propose non-coverage of Cxbladder tests by Medicare, the US national health insurance provider. Read More
Pacific Edge Provides Update on Kaiser EMR Integration
31st March 2023
Pacific Edge today announces it has completed the software development and integration testing on its project to integrate Cxbladder into the Electronic Medical Records (EMR) system of Kaiser Permanente. Read More
Study Adds Support for Cxbladder Monitor Use in Cancer Surveillance
13th March 2023
Pacific Edge today welcomes the release of new research supporting the clinical utility of the company’s genomic biomarker test Cxbladder Monitor in the surveillance for bladder cancer recurrence. Read More
Pacific Edge to Showcase Leading Biomarker Strategies for the Evaluation and Management of Bladder Cancer at SESAUA
08th March 2023
Pacific Edge today announces its key activities and highlights at the 87th Annual AUA Southeastern Section (SESAUA) meeting to be held March 15-18 in Amelia Island, Florida. Read More